MOH
- Marketing authorisation holder: GLAXOSMITHKLINE LLC
- Status: likely_approved
Exdensur (DEPEMOKIMAB) regulatory status in Israel.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
GLAXOSMITHKLINE LLC holds the Israeli marketing authorisation.